期刊文献+

含盖诺化疗方案治疗复发性非霍奇金淋巴瘤的临床观察 被引量:2

NVB and other 4 drugs combining chemotherapy for recurrent intermedium-high risk non-Hodgkin's Lymphoma
暂未订购
导出
摘要 目的 :观察盖诺 (NVB)、卡铂 (CBP)、异环磷酰胺 (IFO)、平阳霉素 (BLM A5 )、强的松 (PDN)组成的NCIBP方案治疗复发性非霍奇金淋巴瘤的近期疗效和毒副反应。方法 :采用NVB40mgivD1,8;CBP0 3ivd1;IFO1 0ivd1-3 Mesna0 4iv于IFO后 0、4、8小时各一次 ,d1-3 ;BLM A5 8mgimBiw× 2。结果 :全组 2 5例 ,CR16例 ,PR4例 ,总有效率 80 %。毒副反应主要是白细胞、血小板下降 ,发生率分别为 84%和 6 0 %,脱发发生率为 96 %。结论 :NCIBP方案治疗复发性非霍奇金淋巴瘤疗效较为满意。 Objective:To observe the efficacy and toxicity of NCIBP combination regime in the treatment of recurrent non-Hodgkins lymphoma using Vinorelbine,Carboplatin,Ifosfamide,Pingyangmycin and Prednisone.Methods:40 mg/m 2 NVB was infused by push on d 1.8;0.3 g CBP iv by drop on d 1;1.0 g IFO iv by drop on day 1-3;0.4 g Mesna iv by drop 0,4,8 hrs after infusion of IFO on d 1-3;8 mg PYM im Biw ×2 with 5 mg DXM before;30 mg PDN orally d 1-14.Every four weeks as one cycle.Assessment was given after two or three cycles.Results:The total response rate in 25 patients was 16/25(80%) with 16 CR and 4 RR.Major toxicity were neutropenia and thrombocytopenia with occurrence rate 84% and 60%,Ⅲ to Ⅳ grade neutropenia are 20%(5/25).Conclusion:NCIBP regime has significant efficiency in the treatment of recurrent non-Hodgkin's lymphoma and worth further clinical study.
出处 《临床肿瘤学杂志》 CAS 2002年第3期224-225,共2页 Chinese Clinical Oncology
关键词 盖诺 复发性 非霍奇金淋巴瘤 临床观察 化学疗法 Combination Chemotherapy Recurrent non-Hodgkin's lymphoma Short-term response
  • 相关文献

参考文献5

二级参考文献14

  • 1孙燕 周际昌.临床肿瘤内科手册(第3版)[M].北京:人民卫生出版社,1996.98.
  • 2UICC 孙燕(译).成人及儿童肿瘤内科手册[M].北京:人民卫生出版社,1998.29.
  • 3唐惟喻 王风英 等.恶性淋巴瘤.现代肿瘤学[M].上海:上海医科大学出版社,1993,9.990.
  • 4金杏泉 赵体平 等.CODBP方案治疗非霍奇金淋巴瘤(附167例疗效和生存分析)[J].中国癌症杂志,1994,4(4):284-284.
  • 5王奇璐,中华肿瘤杂志,1999年,21卷,2期,155页
  • 6孙燕(译),成人及儿童肿瘤内科手册,1998年,29页
  • 7孙燕,临床肿瘤内科手册(第3版),1996年,30页
  • 8金杏泉,中国癌症杂志,1994年,4卷,4期,284页
  • 9唐惟喻,现代肿瘤学,1993年,990页
  • 10管震忠,癌症,1992年,11卷,3期,171页

共引文献768

同被引文献13

  • 1黄丹,余祎.自体外周血造血干细胞移植患者的护理[J].公共卫生与预防医学,2004,15(5):69-69. 被引量:2
  • 2张秋霞,陈长英.自体外周血造血干细胞支持下大剂量化疗治疗淋巴瘤的护理[J].中国误诊学杂志,2005,5(2):358-359. 被引量:2
  • 3Yamazaki T, Kura Y, Sawada U. Treatment of intermddiate and high grade non-Hodgkin's lymphoma[J]. Nippon Rinsho, 2000, 58(3): 695-698.
  • 4Plantier C I, Dupriez B, Simon M, et al. The VIM3-Ara-C regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hoghkin's lymphomas[J]. Leukemia, 1999, 13 (2): 282-288.
  • 5Sarris A H, Romaguera J, Hagemeister F B, et al. Ifinotecan in relapsed or refractory non-Hodgkin's lymphoma [J]. Oncology (Huntingt), 2001,15(7 Suppl 8): 53-56.
  • 6Kraut E H, Balcerzak S P, Young D, et al. A phase Ⅱ study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase Ⅱ research consortium study[J]. Cancer Invest, 2002, 20(2): 174-179.
  • 7Kancherla R R, Nair J S, Ahmed T, et al. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomeraseDNA complex formation with clinical response[J]. Cancer, 2001, 91 (3): 463-471.
  • 8Crump M, Couban S, Meyer R, et al. Phase Ⅱ study of sequential topotecan and etoposide in patients with intermediate grade nonHodgkin's lymphoma:a national cancer institute of Canada clinical trial trials group study[J]. Leuk Lymphoma, 2002, 43(8): 1581-1587.
  • 9刘玲,欧英贤.造血干细胞支持治疗护理学[M].北京:人民卫生出版社,2002:222-223.
  • 10Sook-- Bin W, Stephen T, Michacl M, et al. A Longitudi-- nal study of oralurat ulcerative mucositis in bune marrow trans- plant recipients[J]. Cancer, 1993,16 (2) : 52- 53.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部